Overall survival · Adult patients with myelodysplastic syndromes and thrombocytopenia
1 finding from 1 review
Mortality during study · Adult patients with myelodysplastic syndromes and thrombocytopenia
Thrombopoietin mimetics showed no clear difference in mortality during study compared with placebo (low certainty).
1 finding from 1 review
Transformation to AML · Adult patients with myelodysplastic syndromes and thrombocytopenia
It is very uncertain whether thrombopoietin mimetics changes transformation to AML compared with placebo (very low certainty).
1 finding from 1 review
Incidence of bleeding events · Adult patients with myelodysplastic syndromes and thrombocytopenia
Thrombopoietin mimetics probably leads to lower incidence of bleeding events compared with placebo (moderate certainty).
1 finding from 1 review
Blood transfusion requirements · Adult patients with myelodysplastic syndromes and thrombocytopenia
Thrombopoietin mimetics showed no clear difference in transfusion requirement compared with placebo (low certainty).
1 finding from 1 review
Health‐related quality of life · Adult patients with myelodysplastic syndromes and thrombocytopenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All adverse events · Adult patients with myelodysplastic syndromes and thrombocytopenia
Thrombopoietin mimetics showed no clear difference in all adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Adult patients with myelodysplastic syndromes and thrombocytopenia
It is very uncertain whether thrombopoietin mimetics changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Number of participants with at least 1 bleeding episode · People with chronic bone marrow failure
Thrombopoietin mimetic showed no clear difference in number of participants with at least one bleeding episode compared with placebo (low certainty).
1 finding from 1 review
Number of participants with severe or life‐threatening bleeding · People with chronic bone marrow failure
Thrombopoietin mimetic showed no clear difference in number of participants with at least one severe or life‐threatening… compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · People with chronic bone marrow failure
It is very uncertain whether thrombopoietin mimetic changes all‐cause mortality compared with placebo (very low certainty).
1 finding from 1 review
Proportion of patients receiving platelets · People with chronic bone marrow failure
Thrombopoietin mimetic probably leads to lower proportion of participants receiving a platelet transfusion compared with placebo (moderate certainty).
1 finding from 1 review
Blood transfusion reaction · People with chronic bone marrow failure
1 finding from 1 review
Thromboembolism · People with chronic bone marrow failure
It is very uncertain whether thrombopoietin mimetic changes thromboembolism compared with placebo (very low certainty).
1 finding from 1 review
Adverse drug reactions · People with chronic bone marrow failure
Thrombopoietin mimetic showed no clear difference in drug reactions compared with placebo (low certainty).
1 finding from 1 review
Number of red cell transfusions per participant · People with chronic bone marrow failure
1 finding from 1 review